Aurobindo Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Aurobindo Pharma has a total shareholder equity of ₹281.9B and total debt of ₹66.5B, which brings its debt-to-equity ratio to 23.6%. Its total assets and total liabilities are ₹439.2B and ₹157.3B respectively. Aurobindo Pharma's EBIT is ₹36.8B making its interest coverage ratio 38.4. It has cash and short-term investments of ₹71.5B.
Key information
23.6%
Debt to equity ratio
₹66.49b
Debt
| Interest coverage ratio | 38.4x |
| Cash | ₹71.49b |
| Equity | ₹281.95b |
| Total liabilities | ₹157.29b |
| Total assets | ₹439.24b |
Recent financial health updates
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27
Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well
Nov 27Recent updates
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Apr 14Aurobindo Pharma's (NSE:AUROPHARMA) Dividend Will Be ₹1.50
Feb 11Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Jan 08These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well
Nov 27Aurobindo Pharma's (NSE:AUROPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Nov 10Here's Why Shareholders May Want To Be Cautious With Increasing Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Pay Packet
Aug 19Aurobindo Pharma's (NSE:AUROPHARMA) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 15Financial Position Analysis
Short Term Liabilities: AUROPHARMA's short term assets (₹235.6B) exceed its short term liabilities (₹130.1B).
Long Term Liabilities: AUROPHARMA's short term assets (₹235.6B) exceed its long term liabilities (₹27.2B).
Debt to Equity History and Analysis
Debt Level: AUROPHARMA has more cash than its total debt.
Reducing Debt: AUROPHARMA's debt to equity ratio has reduced from 42.7% to 23.6% over the past 5 years.
Debt Coverage: AUROPHARMA's debt is well covered by operating cash flow (30%).
Interest Coverage: AUROPHARMA's interest payments on its debt are well covered by EBIT (38.4x coverage).